Search for the latest oncology news by tumour type
In an early-phase trial, nearly three-quarters of patients who received talquetamab, a first-in-class experimental immunotherapy…
Second-line treatment with trastuzumab deruxtecan (T-DXd) led to significantly longer overall survival compared with trastuzumab…
Patients with localized, hormone receptor-positive, HER2-low breast cancer treated with trastuzumab deruxtecan (T-DXd, Enhertu) in…
In patients with hormone receptor (HR)-positive, HER2-negative tumours resistant to aromatase inhibitors, addition of the…
The use of circulating tumour cell (CTC) count to guide the choice between chemotherapy and endocrine…
Long-term clinical outcomes from the groundbreaking Trial Assigning Individualized Options for Treatment (Rx) or TAILORx trial continue to show that most…
A small molecule inhibitor that attacks the difficult-to-target, cancer-causing gene mutation KRAS, found in nearly 30…
Researchers at the University of Michigan Rogel Cancer Centre and School of Dentistry in the…
Patients with invasive breast cancer who had low scores on an investigational gene molecular signature had…
Breast cancer patients who paused their endocrine therapy to try to get pregnant experienced short-term…